Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03665675 · ClinicalTrials.gov registry record · Early Phase 1
Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT
A Early Phase 1 study of Adenovirus and Cytomegalovirus, sponsored by Sumithira Vasu.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
- 2
- Study locations
NCT03665675 is a Early Phase 1 study of Adenovirus and Cytomegalovirus that is actively recruiting participants, run by Sumithira Vasu. The registered enrollment target is 20 participants, below the 28-participant average among 6 other Adenovirus trials with a reported enrollment target (29% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT03665675, a Early Phase 1 study of Adenovirus and Cytomegalovirus, is actively recruiting participants, sponsored by Sumithira Vasu.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
- 2
- Study locations
Study Summary
This trial studies the side effects and how well allogeneic cytomegalovirus-specific cytotoxic T lymphocytes (donor cytomegalovirus \[CMV\] specific cytotoxic T-lymphocytes \[CTLs\]) or allogeneic adenovirus-specific cytotoxic T lymphocytes (donor adenovirus-specific \[AdV\] specific CTLs) work in treating CMV or AdV reactivation or infection in participants who have undergone stem cell transplant or solid organ transplant. White blood cells from donors may be able to kill cancer cells in patients with cytomegalovirus or adenovirus that has come back after a stem cell or solid organ transplant.
Conditions Studied
Interventions
- BIOLOGICAL Allogeneic Cytomegalovirus-Specific Cytotoxic T lymphocytes
- BIOLOGICAL Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes
Study Locations (2)
Ohio
- Nationwide Children's Hospital - Columbus
- Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2020-11-07 |
| Est. Completion | 2026-04-20 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03665675
The ClinicalTrials.gov registry entry for NCT03665675 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 28-participant average among 6 other Adenovirus trials with a reported enrollment target (29% lower). The listed sponsor is Sumithira Vasu, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Adenovirus appearing as the primary indexed condition, and to 2 interventions - of which Allogeneic Cytomegalovirus-Specific Cytotoxic T lymphocytes is the first listed.
NCT03665675 reports 2 study locations spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT03665675 about?
NCT03665675 is a clinical study titled "Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT". This trial studies the side effects and how well allogeneic cytomegalovirus-specific cytotoxic T lymphocytes (donor cytomegalovirus \[CMV\] specific cytotoxic T-lymphocytes \[CTLs\]) or allogeneic adenovirus-specific cytotoxic T lymphocytes (donor adenovirus-specific \[AdV\] specific CTLs) work in t...
What is the current status of trial NCT03665675?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2020-11-07. Estimated completion is 2026-04-20.
What conditions does trial NCT03665675 study?
This clinical trial studies the following conditions: Adenovirus, Cytomegalovirus, Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Donor, Solid Organ Transplantation Recipient.
What interventions are being tested in trial NCT03665675?
The interventions under investigation include: Allogeneic Cytomegalovirus-Specific Cytotoxic T lymphocytes (BIOLOGICAL), Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes (BIOLOGICAL).
Who is sponsoring clinical trial NCT03665675?
This trial is sponsored by Sumithira Vasu, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03665675 being conducted?
This trial has 2 study locations across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adenovirus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Haplo-identical Viral-Specific T-cells for Treatment of Cytomegalovirus and Adenovirus Infections After Hematopoietic Cell Transplantation
RECRUITING · Phase 2
-
R-MVST Cells for Treatment of Viral Infections
RECRUITING · Phase 1
-
Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity
RECRUITING · Phase 1
-
R-MVST Cells for Treatment of Viral Infections in Children and Young Adults
RECRUITING · Phase 1
-
Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection
RECRUITING · Phase 2
-
Viral Specific T-Lymphocytes to Treat Adenovirus or CMV
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.